Live Breaking News & Updates on Paclitaxel

FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer

CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.

Thomas-schuetz , Fda , Ctx-009 , Paclitaxel , Fast-track-designation , Metastatic-or-locally-advanced-biliary-tract-cancer ,

Paclitaxel treatment found to directly promote HBV replication and transcription

Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy.

Xia-he-publishing-inc , Hepatitis , Epatitis-b , Hepatitisb-virus , Paclitaxel , Ranscription , Irus , Ssay , Ell , Hronic , Dysbiosis

Drug-coated balloon shows superiority in coronary in-stent restenosis treatment

In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.

Saint-francis-hospital , Washington , United-states , Denver , Colorado , Saint-anthony-hospital , Boston , Massachusetts , J-aaron-grantham , Cinthia-bateman , Mustafai-ahmed , Dominicj-allocco

IPIAD augments standard therapy for pancreatic ductal adenocarcinoma

A new research perspective was published in Oncoscience (Volume 11) on February 7, 2024, entitled, "IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone."

Richarde-kast , Study-center , Drugs , Adenocarcinoma , Ntibiotic , Azithromycin , Hemotherapy , Gemcitabine , Ncology , Paclitaxel , Esearch

A tree that makes a rare anticancer compound is near extinction. Chinese scientists may have an answer

As a critical yew tree becomes scarce, a Chinese study finds new pathway to rare anticancer compound.

Hong-kong , China , Peking , Beijing , Shenzhen , Guangdong , Xiaoguang , Guizhou , Chinese , Yan-jianbin , College-of-chemistry , Chinese-academy-of-agricultural-sciences

#VisualAbstract: No increase in mortality with paclitaxel-coated devices among patients with femoropopliteal disease

1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated analyses groups. Evidence Rating Level: 1 (Excellent) Study Rundown: The safety of paclitaxel-coated devices for femoropopliteal disease has been well-studied; however, a 2018 meta-analysis raised concerns about increased mortality risk with paclitaxel. This meta-analysis aimed to provide

Minute-medicine-inc , Rating-level , Paclitaxel-coated-devices , Peripheral-artery , Femoropopliteal-disease , Femoropopliteal-occlusive-disease , Mortality , Paclitaxel , Studygraphics ,

No increase in mortality with paclitaxel-coated devices among patients with femoropopliteal disease

1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated analyses groups. Evidence Rating Level: 1 (Excellent) Study Rundown: The safety of paclitaxel-coated devices for femoropopliteal disease has been well-studied; however, a 2018 meta-analysis raised concerns about increased mortality risk with paclitaxel. This meta-analysis aimed

Rating-level , Paclitaxel-coated-devices , Peripheral-artery , Claudication , Femoropopliteal-disease , Interventional-radiology , Paclitaxel , Paclitaxel-coated-device , Peripheral-arterial-disease , Peripheral-vascular-disease , Vascular-surgery

Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

San-antonio , Texas , United-states , Antonio-breast-cancer , Immunotherapy , Sabcs , San-antonio-breast-cancer-symposium , Neoadjuvant-nivolumab , Carboplatin , Paclitaxel , Breast-cancer

Lack of Vitamin D May Increase Chemo-Induced Neuropathy Risk in Breast Cancer

Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

United-states , American , Axel-kock , Journal-of-the-national-comprehensive-cancer-network , Image-credit , National-comprehensive-cancer , African-american , Common-terminology-criteria , Adverse-events , Neuropathy , Vitamind-deficiency , Vitamin-d

New study challenges long-held belief about how chemotherapy works

A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.

Danielle-ellis , Mark-burkard , National-institutes-of-health , University-of-wisconsin , Uw-carbone-cancer-center , Beth-weaver , National-institutes , Chemotherapy , Rug-discovery , Rugs , Ancer , Ell